Our own studies of IDH-wildtype GBM have demonstrated that while MGMT promoter methylation analysis is important in the vast majority of these cases, it may be of limited value in cases without at least one of the cIMPACT-NOW update 3 factors [127]. The gene discussed is IDH2; the disease is glioblastoma.